Safety, efficacy, and biological data of T cell-enabling oncolytic adenovirus TILT-123 in advanced solid cancers from the TUNIMO monotherapy phase I trial.
Pakola SA, Peltola KJ, Clubb JHA, Jirovec E, Haybout L, Kudling TV, Alanko T, Korpisaari R, Juteau S, Jaakkola M, Sormunen J, Kemppainen J, Hemmes A, Pellinen T, van der Heijden M, Quixabeira DCA, Kistler C, Sorsa S, Havunen R, Santos JM, Cervera-Carrascon V, Hemminki AE.
Pakola SA, et al. Among authors: santos jm.
Clin Cancer Res. 2024 Mar 28. doi: 10.1158/1078-0432.CCR-23-3874. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 38546220